Fox Business - The Power to Prosper
Search Site

Gilead Sciences

Julian Robertson: The dollar will continue to strengthen

Tiger Management Chairman Julian Robertson discusses currencies, the European economies, first-quarter earnings and the markets.

Read More

  1. Stocks to watch: CMG, DIS

    Rosenthal Wealth Management Group President Larry Rosenthal, Spectrum Management Group Managing Partner Bob Phillips, OptionPit.com founder Mark Sebastian and FBN’s Nicole Petallides on the state of the markets.

  2. Market check: TSLA, NFLX, GILD, FB

    FBN’s Nicole Petallides with the latest on the markets.

  3. Where to find value in today’s market

    Silvant Capital Management managing director Michael Sansoterra gives insight into today’s market.

  4. Sectors seeing growth now

    Brick Investment Partners managing director Chris Thorpe and Landcolt Capital founder Todd Schoenberger discuss their outlook for the economy and markets.

  5. Dow hits all-time high of 17,000

    Stifel Nicolaus portfolio manager Chad Morganlander says the Dow hitting 17,000 shows the economy is on the mend.

  6. Oracle’s $10B bond

    FBN’s Liz MacDonald on Oracle’s $10B bond offering.

  7. Health care sector drags on the S&P

    FBN’s Liz MacDonald with an update on stocks.

  8. Second tech bubble?

    Deutsche Bank senior U.S. economist Carl Riccadonna and BMO Capital Markets chief investment strategist Brian Belski on whether we’re in the second tech bubble in 15 years.

  9. What to expect from pharma

    Robert W. Baird & Co. senior analyst Brian Skorney on what investors can expect from pharma in the second quarter.

  10. Gilead Profit Triples On Hepatitis C Drug Revenue

    Gilead Sciences Inc (NASDAQ:GILD), which ignited a fierce debate over prescription drug prices, said its new $1,000 hepatitis C pill generated quarterly sales of $2....

  11. Gilead Beats Expectations; Sovaldi Sales Hit $2.3 Bln

    Gilead Sciences Inc. reported late Tuesday its first-quarter net income rose to $2.23 billion, or $1.33 per diluted share, from $722.2 million, or 43 cents per dilut...

  12. Rallying Ahead of Earnings

    A handful of companies due to report earnings this afternoon are rallying into the close.  Note that biotechs Gilead Sciences and Amgen are advancing the most:Rallyi...

  1. Midday Market Report: 3/23/15

    Delphi Automotive's driveless car on a cross country road trip

  2. Nasdaq hits 5,000

    FBN’s Maria Bartiromo, Jo Ling Kent and Liz MacDonald discuss the Nasdaq hitting 5,000.

  3. Hot Nasdaq stocks to buy

    FBN’s Charles Payne, Kaltbaum Capital Management President Gary Kaltbaum, Fairfax Global Markets CEO Paul Dietrich, A&G Capital CIO Hilary Kramer and Penn Financial Group founder Matt McCall on the Nasdaq stocks to boost investors’ portfolios.

  4. Lackluster earnings so far

    NRF Vice President Jonathan Gold discusses the economic impact of a full port shutdown.

  5. Outlook for earnings season

    Estimize Senior Vice President Christine Short discusses her predictions for earnings and revenue.

  6. Dow breaks through 18K for first time

    FBN’s Tracy Byrnes on the state of the U.S. markets and economy.

  7. J.C. Penny earning slip signaling a market crash?

    Belpointe Chief Strategist David Nelson explains why J.C. Penny is in trouble and whether stocks are headed for a crash.

‹ Prev12345Next ›
Freebase CC-BY
Source: Gilead Sciences on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL